In the present study, ER was positive in 1 (1/9, 11.11%) patient; PR was positive in 2 (2/9, 22.22%) patients; ER, PR and HER2 were negative in 5 masses (5/9, 55.56%, triple-negative breast cancer); 4 patients of the above triple-negative breast cancer were pure SCCs. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.